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Cost-effectiveness of artificial intelligence 
aided vessel occlusion detection in acute stroke: 
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Abstract 
Background: Limited evidence is available on the clinical impact of artificial intelligence (AI) in radiology. Early 
health technology assessment (HTA) is a methodology to assess the potential value of an innovation at an early stage. 
We use early HTA to evaluate the potential value of AI software in radiology. As a use-case, we evaluate the cost-
effectiveness of AI software aiding the detection of intracranial large vessel occlusions (LVO) in stroke in comparison 
to standard care. We used a Markov based model from a societal perspective of the United Kingdom predominantly 
using stroke registry data complemented with pooled outcome data from large, randomized trials. Different scenarios 
were explored by varying missed diagnoses of LVOs, AI costs and AI performance. Other input parameters were varied 
to demonstrate model robustness. Results were reported in expected incremental costs (IC) and effects (IE) expressed 
in quality adjusted life years (QALYs).
Results: Applying the base case assumptions (6% missed diagnoses of LVOs by clinicians, $40 per AI analysis, 50% 
reduction of missed LVOs by AI), resulted in cost-savings and incremental QALYs over the projected lifetime (IC: 
− $156, − 0.23%; IE: + 0.01 QALYs, + 0.07%) per suspected ischemic stroke patient. For each yearly cohort of patients 
in the UK this translates to a total cost saving of $11 million.
Conclusions: AI tools for LVO detection in emergency care have the potential to improve healthcare outcomes 
and save costs. We demonstrate how early HTA may be applied for the evaluation of clinically applied AI software for 
radiology.
Keywords: Stroke, Artificial intelligence, Cost–benefit analysis, Computed tomography angiography, Endovascular 
procedures
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Key points
• Early health technology assessment can be used to 
assess impact of AI.
• The use of AI for large vessel occlusion detection may 
be cost-effective.
• Increased health and costs savings are expected over 
the projected lifetime.
• Financial investments and benefits are allocated dif-
ferently, challenging adoption.
Background
Currently, there are more than one hundred CE-certified 
artificial intelligence (AI) software products for radiol-
ogy on the market, addressing a wide range of applica-
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healthcare and increasing efficiency, however evidence 
on its impact on healthcare is generally lacking [1]. For 
detection of acute ischemic stroke specifically, six regula-
tory cleared (CE and/or FDA) AI products are commer-
cially available that detect large vessel occlusions (LVOs) 
on computed tomography angiography (CTA). The main 
aim of these products is to improve the diagnostic accu-
racy of LVOs, while fast and accurate diagnosis is crucial 
to provide appropriate treatment, especially when intra-
arterial thrombectomy (IAT) is possible, which overall 
results in improved patient outcome [2–4].
There is some evidence on the stand-alone diagnostic 
accuracy of LVO detection software in peer-reviewed 
publications (n = 2) and FDA submissions (n = 3) indicat-
ing radiologist-level performance regarding sensitivity 
[5–9]. However, limited research has yet been published 
on the added value of these algorithms on the diagno-
sis, treatment decisions, patient outcomes and societal 
outcomes [10]. It therefore remains unknown to what 
extend the use of AI software for LVO detection impacts 
the diagnostic accuracy and, consequently can impact 
healthcare outcomes and overall costs.
Early health technology assessment (HTA) is a meth-
odology to assess the potential value of an innovation in 
an early stage before it has been implemented [11, 12]. 
The aim of early HTA is to provide insight in the poten-
tial value of new technology to inform about further 
development (is it worthwhile to further develop the 
technology and perform research on the technology), 
positioning of the technology within the treatment path-
way (for instance should it be an addition to the current 
pathway or replace something else), required specifica-
tions (minimal needed effectiveness, pricing) and future 
research (what outcomes should be included in future 
clinical research). Outcomes provide guidance in allocat-
ing healthcare resources in an efficient way promoting 
value-based healthcare. We hypothesize that early HTA 
is also a useful method to assess the potential impact of 
AI applications on healthcare outcomes and costs. There-
fore, the aim of this study, was to use early HTA to evalu-
ate the potential cost-effectiveness of using an AI tool in 
ischemic stroke for intracranial LVO detection on com-




To demonstrate the potential value of AI-aided LVO 
detection, two strategies were compared with regards 
to costs and effects. The first strategy comprised cur-
rent standard of care. Patients receive head CTA with or 
without CT perfusion (CTP) when suspected of ischemic 
stroke based on symptoms and exclusion of other causes 
as demonstrated by non-contrast CT. The images are 
evaluated by a radiologist and/or neurologist on duty 
after which IAT follows if the patient is deemed eligible 
according to current guidelines [13].
The second strategy was defined as a theoretical strat-
egy in which AI is used as an aid for LVO detection on 
CTA. For both strategies, only vessel occlusions in the 
proximal anterior circulation (ICA, A1, M1, M2) were 
regarded as relevant for patient selection to IAT as in 
concordance with the recommendations in the current 
stroke guidelines [13]. In this strategy, we assume that AI 
software is capable of increasing the diagnostic sensitiv-
ity, especially for the detection of M2 occlusions, without 
a decrease in specificity. False positives of the AI software 
are expected to be neutralized by the judgement of the 
reader in order to prevent overtreatment.
Some vendors claim that, besides providing a more 
accurate diagnosis, the use of AI may lead to shorter time 
to treatment, especially when it enables to bypass the 
radiologist [10]. As most currently available commercial 
products focus on triage and interactive decision sup-
port, we only assessed the claim that the use of AI could 
provide a more accurate diagnosis, i.e. reduce the num-
ber of missed LVOs.
Model structure
We used a Markov model to demonstrate the costs and 
health outcomes of the two strategies. The decision tree 
represents the acute phase (first 90 days) for both strate-
gies (Fig. 1). The modified Rankin Score (mRS), describ-
ing the level of disability, at 90 days was the initial state 
for the subsequent Markov model to model outcomes 
over a lifetime horizon. After each yearly cycle, over a 
total of 70 cycles, patients could remain in their current 
health state, have a recurrent stroke, or die according to 
mortality probabilities of the general population [14]. The 
analysis was conducted from a societal perspective in the 
context of the United Kingdom. Modelling was done in 
Microsoft Excel 16.
Population
We based our cohort (n = 71,840) predominantly on 
stroke registry data from the UK [15]. The initial cohort, 
on which the AI software would be applied, consisted of 
patients that received CTA in the diagnostic work-up of 
acute stroke. We excluded late presenters of stroke (last 
seen well > 4 h) as available mRS data was based on early 
presenters. Of the patients, 30.6% had a LVO, of whom 
43.8% were eligible for IAT treatment [15].
Little is known about the percentage of missed LVOs 
in standard of care, but estimates ranging between 6 and 
20% have been reported in literature [16, 17]. We there-
fore test a range of this variable in our model and zoom 
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in to the conservative scenario where 6% of LVOs are 
missed. This number was based on an observer study 
with three neuroradiologists using CTAs and CTPs for 
LVO detection [16].
Other variables needed to complete the model were 
compiled from previously performed large stroke stud-
ies. Population age was set at 66 years based on the MR 
Clean trial [3]. mRS outcomes at 90  days were based 
on pooled data from large randomized trials (SWIFT 
PRIME, MR CLEAN, REVASCAT, EXTEND-IA, 
ESCAPE) [2]. The yearly average probability for recurrent 
stroke after the acute phase (first 90 days) was 2.84% [18]. 
Recurrent stroke in the acute phase was included in the 
mRS outcome at 90 days. In patients who suffered from a 
recurrent stroke worse outcome with higher mRS states 
were possible. mRS state distribution in patients with a 
recurrent stroke were assumed to be equal to a group 
of patients who did not receive IAT. Table 1 provides an 
overview of these model inputs.
Costs
Costs were derived from a previous study (Table 2) [19]. 
Short term costs (< 90 days) consisted of costs for treat-
ment, hospitalization and management of adverse events. 
Long term costs were attributed to the different mRS 
states, based on the OXVASC study, including costs of 
personal social services, such as nursing and residential 
care costs [20].
All costs were inflated to the level of 2019 according 
to the Consumer Price Index from the Office of National 
Statistics of the UK and were discounted at 4% annually 
[21, 22]. We report all costs in US dollars to ease inter-
pretation by applying the 2019 average exchange rate 
(£1 = $1.283) [23].
Health outcome
The health outcomes have been described in quality 
adjusted life years (QALYs) with 0 meaning death and 
1 being in perfect health. The mRS scores were utility 
weighted based on the MR Clean trial (Table 3) [26]. Util-
ities were discounted at a rate of 1.5% annually [21].
Analysis
In multiple-scenario analyses we assessed the differences 
in health outcomes and costs at different algorithm per-
formance values (percentage of LVOs detected by the 
AI tool that would have otherwise been missed), costs 
of the AI tool (US dollar per analysis) and percentage of 
missed LVOs in standard of care. A base case analysis 
was performed using a combination of assumptions for 
these parameters. The sensitivity of AI tools validated 
stand-alone for detection of LVOs have been reported 
to be in the range of 87.8–97.9% [5–8]. However, for this 
analysis it is relevant to know how much the diagnostic 
accuracy improves when a radiologist uses the AI tool as 
a detection aid. As there is no evidence available on the 
percentage of reduced missed LVOs through the use of 
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Fig. 1 Decision tree applicable to the standard of care strategy and the AI tool strategy. In the AI tool strategy the ratio of occlusions (not) detected 
was altered. CTA, computed tomography angiography, IAT, intra-arterial thrombectomy
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commercial AI products, we varied this number around 
an assumed base case performance of 50%. The price of 
the AI per case was set at $40 for the base case scenario. 
As previously described the base case assumption of 
missed LVOs in standard of care was set at 6%.
The reference value for one QALY was £20,000 
($25,662) [27]. We performed multiple one-way sensi-
tivity analyses in which we varied the parameters that 
were not included in the scenario analysis to evaluate the 
robustness of the model.
This was an observational study for which the Institu-
tional Review Board approval was waived. The model is 
made available on https:// www. AIfor Radio logy. com with 
the possibility to adapt the variables [28].
Results
Applying AI for LVO detection has the potential to save 
costs and increase patient outcomes. Table  4 shows the 
outcomes in different scenarios regarding the percent-
age of missed LVOs in usual care and the percentage of 
missed LVOs that are detected by the innovation. No 
costs for the innovation were included in these analyses. 
Therewith, the potential cost savings represent the maxi-
mum costs for the innovation at which the innovation is 
dominant over usual care, i.e., results in both health gain 
and cost savings. For example, with 1% of current missed 
LVOs and 25% of detection with the innovation the maxi-
mum costs per AI analysis could be $16 for the innova-
tion to be dominant.
Figure  2 illustrates the cost saving per patient when 
varying the costs per AI analysis and the percentage 
reduction of missed LVOs by the AI tool, assuming a cur-
rent missed LVO rate of 6%. Here, it becomes apparent 
at what cost or performance the AI tool will be cost sav-
ing. The filled green bullet demonstrates the base case 
scenario (6% missed diagnoses, $40 per AI analysis, 50% 
reduction of missed LVOs by AI). Table  5 zooms in on 
the results of the base case scenario. Here, the model pre-
dicted that the AI strategy results in both cost reduction 
and improved patient outcome compared to the standard 
of care. For the projected lifetime per ischemic stroke 
patient, the incremental costs and incremental efficacy 
were − $156 (− 0.23%) and + 0.0095 QALYs (+ 0.07%) 
respectively. Using the reference value of $25,662 per 
QALY, 0.0095 QALY would translate to $244. For each 
yearly cohort of patients in the UK this translates to a 
total cost saving of $11 million and QALY gain of 682 
($17.5 million).
Within a ninety-day window, the intervention scenario 
led to incremental costs (IC: + $60) due to the increased 
Table 1 Model input—clinical parameters
LVO, large vessel occlusion; CTA, computed tomography angiography; IAT, intra-arterial thrombectomy; mRS, modified Rankin Scale
Model Input Base case Reference
LVO missed standard care 6% Becks et al. [16]
Reduction of missed LVO through AI detection (varied) 50%
LVO of patients suspected of stroke receiving CTA 30.6% McMeekin et al. [15]
IAT eligible of LVO population 43.8% McMeekin et al. [15]
Population age 66 MR Clean Trial [3]
mRS after LVO treated with IAT Aronsson et al. [2]
 mRS 0 11%
 mRS 1 18%
 mRS 2 20%
 mRS 3 17%
 mRS 4 16%
 mRS 5 4%
 Death 14%
mRS after LVO treated without IAT Aronsson et al. [2]
 mRS 0 5%
 mRS 1 8%
 mRS 2 11%
 mRS 3 17%
 mRS 4 27%
 mRS 5 12%
 Death 20%
Probability of recurrent stroke 2.84% Pennlert et al. [18]
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utilization of the more expensive IAT treatment. Negli-
gible healthcare improvement (IE: + 0.0001 QALY) was 
observed. A cost reduction and larger QALY gain are 
expected for the lifetime duration after the acute phase 
(IC: − $216, IE: + 0.0094 QALY).
Figure  3 shows the results of the one-way sensitivity 
analysis taking the base case scenario as its starting point. 
In all cases the incremental costs remained negative and 
the incremental efficacy positive. The long-term stroke 
costs was the parameter causing most variation in the 
results followed by the starting age of the patient popu-
lation. Sensitivity analyses of the mRS probabilities and 
utility values are reported in the Additional file  1. The 
analyses did not include extra costs for possible increased 
reading time for false positive cases as this only resulted 
in neglectable extra costs − $0.07 for each percentage 
point of false positives—as shown in the Additional file 2.
Discussion
We applied early health technology assessment (HTA) 
to demonstrate the potential cost-effectiveness of an AI 
tool. Current AI research focuses mainly on the perfor-
mance of algorithms (the means) instead of assessing the 
impact on healthcare outcomes and costs, especially in 
the early stage of development.
In this study, we demonstrate with the use of early 
HTA that AI software for the aided detection of intracra-
nial LVO in ischemic stroke has the potential to improve 
healthcare outcomes and save overall costs. The sensitiv-
ity analyses demonstrate the robustness to variation of 
model parameters and assumptions. The improved LVO 
detection leads to better clinical outcome on both the 
Table 2 Model input—costs
* Cost of the average treatment was adjusted for the estimated frequency of the treatment according to different studies. For IAT eligible patients, we assumed 85% 
to receive both IAT and intravenous thrombolysis (IVT), 10% to receive IAT only, and 5% to receive IVT and going for IAT but who appeared revascularised during 
angiography [3, 15, 24]. For non-IAT-eligible patients we assumed 40% to receive IVT based on previous study and our local medical center data[25]
IAT, intra-arterial thrombectomy; mRS, modified Rankin Scale Costs are rounded to the nearest integer
Costs Base case Reference
Cost algorithm per analysis (varied) $40
Treatment costs*
 Average costs IAT eligible $11,728 Lobotesis et al. [19], Berkhemer et al. [3], McMeekin 
et al. [15], Mulder et al. [24]
 Average costs non-IAT eligible $1004 Lobotesis et al. [19], Bandettini di Poggio et al. [25]
Acute stroke costs (< 90 days) Lobotesis et al. [19]
 mRS 0 $4350
 mRS 1 $5117
 mRS 2 $5885
 mRS 3 $22,695
 mRS 4 $30,704
 mRS 5 $36,468
 mRS 6 (death) $4603
Long term stroke costs (annually) Lobotesis et al. [19]
 mRS 0 $3936
 mRS 1 $4631
 mRS 2 $5325
 mRS 3 $18,944
 mRS 4 $25,631
 mRS 5 $41,621
Discount costs 4% Guideline for economic evaluations in healthcare [21]
Table 3 Model input—utility values
mRS, modified Rankin Scale
Utility Dijkland et al. [26]
 mRS 0 0.95
 mRS 1 0.93
 mRS 2 0.83
 mRS 3 0.62
 mRS 4 0.42
 mRS 5 0.11
Discount utilities 1.5% Guideline for economic 
evaluations in health-
care[21]
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Table 4 Potential change in costs and QALYs when applying AI tool as opposed to usual care
Costs and QALYs are per patient receiving CTA with indication stroke, when applying AI tool as opposed to usual care with varying ratio of missed LVOs in current care 
and varying rates of reduction in missed LVOs due to innovation. No costs for the AI innovation were included in this analysis
QALY, quality-adjusted life-year
Costs are rounded to the nearest integer
% LVOs missed usual 
care
% of missed LVOs detected by innovation



















































Fig. 2 Scenario analysis demonstrating incremental costs. Incremental costs at varying prices for the AI tool per analysis ($0–$200) and varying 
percentage of reduction of missed large vessel occlusion diagnoses (0–100%). Green circles demonstrate a cost reduction whereas red circles 
signify an increase in costs. The size of the circle is related to the height of the incremental costs
Table 5 Results of base case analysis* as the difference between usual care and applying the AI tool
* Base case parameters: missed LVOs, 6%; costs per analysis, $40; reduction of missed LVOs, 50%
QALY, quality-adjusted life-year
Costs are rounded to the nearest integer
Incremental costs ($) Incremental efficacy (QALYs)
Population Patient % of usual care Population Patient % of usual care
Acute phase (< 90 days) $4,295,152 $60 0.60 9.45 0.0001 0.06
Rest of life phase (> 90 days) − $15,510,277 − $216 − 0.36 672.82 0.0094 0.07
Total − $11,215,125 − $156 − 0.23 682.27 0.0095 0.07
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short term as well as long term resulting in reduced over-
all healthcare consumption.
Early HTA analyses are not meant to provide a firm 
‘go’ or ‘no-go’ recommendation for the development or 
purchasing of an innovation, but provide insights in the 
direction to head regarding development, implementa-
tion and reimbursement [11]. For example in this study, 
the analyses show that cost benefits are obtained in the 
long term, while the costs for the software are short term 
and are usually covered by the radiology department or 
hospital. This observation could contribute to the debate 
on the investments, financial accountability and reim-
bursement for the clinical use of AI technology.
The difficulty with doing an early HTA is that not all 
data is yet known, hence it is called ‘early’. Therefore, we 
used data from previous studies and made some assump-
tions to complete the model. The sensitivity analysis 
described, demonstrates the effects when varying the 
parameters and provides context on the bias and confi-
dence. The model is made publicly available to allow for 
personalization of the model and the results by adapting 
the parameter values.
One of the main assumptions was the percentage of 
missed LVOs. This was assumed to be 6% for the base 
case scenario, but may vary depending on the clini-
cal context [16, 17]. Because of the limited evidence, we 
based this rate on a study with two neuroradiologists and 
one neuroradiology resident as observers. However, in 
many clinical settings there might not be a specialized 
physician within reach. Some centers have limited expo-
sure to stroke patients and during out-of-office hours the 
studies are generally first evaluated by less experienced 
observers (residents). We therefore consider 6% to be a 
conservative estimate. With higher percentages of missed 
LVOs, the benefits of the use of the AI software increase.
Also, we made an assumption on the capability of the 
AI to reduce missed LVOs in the base case scenario as 
there is limited evidence of the added value of AI tools in 
LVO detection. The results of this study only hold, pro-
vided that AI tools have a positive impact on the diagnos-
tic accuracy of LVOs. Therefore, we have demonstrated 
the effects for an AI tool with the capability to reduce the 
percentage of missed LVOs in the range of 0% to 100%. It 
should be noted that this percentage cannot be directly 
translated to the sensitivity of an AI-algorithm applied 
stand-alone (ranging between 87.8% and 97.9% [5–8]), as 
we assume that the cases that were missed by a physician 
are also more likely to be missed by an algorithm (e.g. M2 
occlusions). For that reason we went for a conservative 
50% reduction of missed diagnoses in the base case sce-
nario and we advise to not use sensitivity measures pro-
vided by a vendor directly as the input to this model.
There are some points of note to our analysis. First, in 
this economic evaluation, we considered a pay-per-use 
business model and assume costs per analysis. When 
vendors employ a software license model, the proposed 
evaluation method can still be applied. By dividing the 
yearly license fee by the expected population, one obtains 
an estimate of the per-analysis costs.
Second, we used data from early-presenters as the 
healthcare outcome data was available for this group 
only. Currently the indication for IAT is being expanded 
Fig. 3 Results of one-way sensitivity analysis. The effect of varying several parameters is shown. In the left diagram the impact on the costs is 
demonstrated and in the right diagram the impact on the QALYs. Light gray bars represent lower bounds, dark gray bars upper bounds. The axis 
intersects at the base case results of − $156 and 0.0095 QALY. LVO, large vessel occlusion; IAT, intra-arterial thrombectomy; QALY, quality-adjusted 
life-year
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to also include late presenters [13]. The majority of the 
UK cohort (86%) was made up of early presenters. We 
hypothesize that cost savings and health gain remain pos-
itive, but will be slightly reduced when including the late 
presenters in the model. Other AI tools aimed at assess-
ing eligibility for IAT, such as CTP analysis, collateral 
status assessment, or ASPECT scoring may have more 
impact on the late presenting population, but are beyond 
the scope of this study.
Lastly, we did not elaborately take into account the 
interaction between the physician and the AI software. 
We expect limited effects of false positives when present 
at an acceptable rate. We assumed that false positive pre-
dictions of the AI software would be neutralized by the 
reader and would not lead to unnecessary invasive pro-
cedures (diagnostic subtraction angiogram). False posi-
tives may contribute to a slightly longer reading time, 
while true positives may speed up the reading process. As 
shown in the sensitivity analyses the slightly extra reading 
time resulted in neglectable extra costs.
In this work, we compared standard of care with use of 
an AI tool to increase diagnostic efficacy in LVO detec-
tion in ischemic stroke. Depending on the center and the 
way that stroke care is organized, there may be alterna-
tive strategies or a combination of strategies to reach the 
same goal that we did not consider, such as the use of 
advanced imaging techniques including CTP, additional 
training of the physicians interpreting the CTA scans, 
a dedicated (neuro)radiologist on call outside of office 
hours, or even other types of AI tools. In further cost-
effectiveness studies these alternatives could be explored 
to determine if implementing an AI tool for LVO detec-
tion is the most cost-efficient solution.
Conclusion
We demonstrate the potential cost-effectiveness of com-
puter aided LVO detection in ischemic stroke by per-
forming an early health technology assessment. Such 
analysis can be used to indicate the potential efficacy of 
an AI tool in an early phase to guide development and 
implementation. The most important next step is to vali-
date the outcomes of the early health technology assess-
ment in clinical practice. With increasing number of AI 
tools implemented in the clinic, it is important to assess 
the impact of AI tools on our healthcare system. Real-life 
outcome measures should be used to gain insights into 
how to apply AI tools in a sensible and safe way. This is a 
prerequisite to prove the claim that AI is making health-
care better and more affordable.
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